STAT Plus: Wegovy and Zepbound get primetime treatment
Today's biotech news includes a pioneering new gene therapy for MLD, the plight of WuXi AppTec in the U.S., and more.
Read The StoryPolitics
STAT has a team of reporters covering health care politics and policy out of Washington, D.C., bringing you the latest from the halls of Capitol Hill, from the White House podium, and from inside key agencies like the FDA, HHS, CDC, and NIH.
STAT offers breaking news, investigations, and features about the ways policymakers’ decisions affect the pharma, biotech, hospitals, insurance, health tech and medical device industries — and how those industries, in turn, are working hard and spending big to affect policy, too.
The team is covering everything from drug pricing to Medicare regulation. We’re tracking major politicians’ health- and science-focused campaign promises and key Supreme Court decisions that affect the U.S. health care landscape.
To get the latest health care politics and policy news delivered to your inbox, sign up for our free, twice-weekly D.C. Diagnosis newsletter. And subscribe to STAT+ for inside intelligence on all these issues and more.
Supreme Court questions restricting government efforts to limit Covid-19 misinformation
STAT Plus: Inside a push to create an NIH office for post-infection chronic illness
STAT Plus: Contineum Therapeutics files for IPO
STAT Plus: BIO severs ties with WuXi in the face of U.S. government concerns over China
All Coverage
advertisement
